Business Wire

ADVA

28.7.2022 07:02:06 CEST | Business Wire | Press release

Share
ADVA increases revenues for Q2 2022

ADVA (ISIN: DE0005103006, FSE: ADV), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported final financial results for Q2 2022 ended on June 30, 2022. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220727005735/en/

Q2 2022 financial summary 1

(in thousands of EUR)

 

Q2 2022

 

Q2 2021

 

Change

 

Q1 2022

 

Change

Revenues

 

166,320

 

149,354

 

11.4%

 

170,498

 

(2.5)%

Pro forma gross profit

 

54,336

 

57,274

 

(5.1)%

 

53,405

 

1.7%

in % of revenues

 

32.7%

 

38.3%

 

(5.6) pp

 

31.3 %

 

1.4 pp

Pro forma EBIT

 

6,435

 

14,415

 

(55.4)%

 

7,812

 

(17.6)%

in % of revenues

 

3.9%

 

9.7%

 

(5.8) pp

 

4.6%

 

(0.7) pp

Operating income 2

 

4,655

 

13,036

 

(64.3)%

 

5,976

 

(22.1)%

Net income

 

7,291

 

12,001

 

(39.2)%

 

6,179

 

18.0%

 

 

 

 

 

 

 

 

 

 

 

(in thousands of EUR)

 

Jun. 30, 2022

 

Jun. 30, 2021

 

Change

 

Mar. 31, 2022

 

Change

Cash and cash equivalents

 

63,187

 

85,023

 

(25.7)%

 

73,002

 

(13.4)%

Net cash (+)/net debt (-)

 

(946)

 

3,876

 

(124.4)%

 

763

 

(224.0)%

Net working capital

183,030

 

132,767

 

37.9%

 

164,402

 

11.3%

1 Potential inconsistencies in the table values are based on rounding differences.
2 Q2 2022 including EUR 0.4 million and Q1 2022 including EUR 0.5 million extraordinary expenses.

Q2 2022 IFRS financial results

Revenues in Q2 2022 reached EUR 166.3 million, down by 2.5% from EUR 170.5 million in Q1 2022 and up by 11.4% compared to EUR 149.4 million in Q2 2021. The increase in revenues for Q2 2022 is predominantly driven by a growth in demand from network operators and internet content providers (ICPs). In addition, the stronger US dollar led to higher revenues in North America.

Pro forma gross profit in Q2 2022 increased by 1.7%, reaching EUR 54.3 million (32.7% of revenues) compared to EUR 53.4 million (31.3% of revenues) in Q1 2022 and decreased by 5.1% compared to EUR 57.3 million (38.3% of revenues) reported in Q2 2021. Gross profit was impacted by increased purchasing costs caused by the semiconductor crisis and a stronger US Dollar.

Pro forma EBIT for Q2 2022 was EUR 6.4 million (3.9% of revenues) and decreased by 17.6% compared to EUR 7.8 million (4.6% of revenues) reported in Q1 2022 and substantially declined by 55.4% from EUR 14.4 million (9.7% of revenues) in Q2 2021.

Operating income for Q2 2022 of EUR 4.7 million decreased by 22.1% from EUR 6.0 million reported for Q1 2022 and significantly decreased by 64.3% from EUR 13.0 million in Q2 2021. Operating income for Q2 2022 was impacted by extraordinary expenses in connection with the announced merger with Adtran amounting to EUR 0.4 million (Q1 2022 EUR 0.5 million and Q2 2021 EUR 0).

Net income reached EUR 7.3 million in Q2 2022, increased by 18.0% from EUR 6.2 million in Q1 2022, and considerably decreased by 39.2% from EUR 12.0 million in Q2 2021.

The company’s cash and cash equivalents totaled EUR 63.2 million, representing a decrease of EUR 9.8 million compared to EUR 73.0 million at the end of Q1 2022. Year-over-year cash and cash equivalents decreased by EUR 21.8 million from EUR 85.0 million at the end of Q2 2021. The company invested non-operating cash in measures to secure delivery.

Net debt at the end of Q2 2022 stood at EUR 0.9 million compared to a net cash position of EUR 0.8 million at the end of Q1 2022 and a net cash position of EUR 3.9 million at the end of Q2 2021.

At quarter-end, net working capital totaled EUR 183.0 million and increased by EUR 18.6 million compared to EUR 164.4 million at the end of Q1 2022 and increased significantly by EUR 50.3 million compared to EUR 132.8 million at the end of Q2 2021. The higher net working capital compared to the year-ago quarter is mainly attributable to increased inventory levels to secure the supply chain.

Management commentary

“The recent months were very exciting for us as a company,” said Brian Protiva, CEO of ADVA. “We reached several important milestones on our journey of joining forces with Adtran and advanced our operational business. Our revenues in the first half of 2022 were at a record level, and our order books are nicely filled. We still see strong customer demand paired with a high level of complexity and costs in the areas of procurement, production and logistics. This environment will continue for the foreseeable future. Our teams work tirelessly on solutions to meet market demand, and we work closely with our customers every day to provide the best possible support for their network development. So far, we’ve mastered the challenges very well and look positively towards the remainder of the year.”

“In the past quarter, we again grew compared to the year-ago quarter. This underlines the positive market environment and the tailwind we are experiencing on the demand side,” said Uli Dopfer, CFO of ADVA. “However, in the second half of the year, we will also have to deal with the challenges resulting from increased procurement costs and stressed supply chains. Despite increased inventories, our liquidity is at a satisfying EUR 63 million. Against the background of a continued strong order intake and a strengthening dollar in combination with persistently higher costs in the supply chains, we have decided to adjust the outlook for the fiscal year accordingly, which we announced in an ad-hoc notification on July 15th. We are raising our revenue guidance to between EUR 680 and 730 million and reducing our pro forma EBIT margin guidance by one percentage point to between 5% and 9%.”

2022 financial outlook

For the fiscal year 2022, ADVA expects revenues to be in the range of EUR 680 million and 730 million and a pro forma EBIT of between 5.0% and 9.0% of revenues.

The company will publish its financial results for Q3 2022 on October 27, 2022.

Conference call details

ADVA will hold a conference call for analysts and investors today, July 28, 2022, to discuss the Q2 2022 results. The company’s CEO, Brian Protiva, CTO, Christoph Glingener, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CEST (9:00 a.m. EDT). A question and answer session will follow management presentations.

A corresponding presentation is available on ADVA’s website:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls

The complete half-year report 2022 (January – June) is available as a PDF here:
https://www.adva.com/en/about-us/investors/financial-results/financial-reports

A replay of the call will be available here:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls

Forward-looking statements

The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.

Use of pro forma financial information

ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, non-recurring expenses related to M&A and restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye